within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB10_Amrubicin;
model Amrubicin 
   extends Pharmacolibrary.Drugs.ATC.L.L01DB10;

  annotation(Documentation(
    info ="<html><body><p>Amrubicin is a synthetic anthracycline antitumor agent used in the treatment of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). It acts primarily as a topoisomerase II inhibitor. Amrubicin is approved for use in some countries, such as Japan, primarily for lung cancer treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were assessed in adult Japanese patients with advanced non-small cell lung cancer and small cell lung cancer following intravenous administration.</p><h4>References</h4><ol><li><p>Hamada, A (2005). [Development of an individualized therapy for establishing the optimal dosage by the pharmacokinetics profiles of anticancer agents]. <i>Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan</i> 125(8) 631–637. DOI:<a href=&quot;https://doi.org/10.1248/yakushi.125.631&quot;>10.1248/yakushi.125.631</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16079613/&quot;>https://pubmed.ncbi.nlm.nih.gov/16079613</a></p></li><li><p>Yanaihara, T, et al., &amp; Masuda, N (2007). Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer. <i>Cancer chemotherapy and pharmacology</i> 59(4) 419–427. DOI:<a href=&quot;https://doi.org/10.1007/s00280-006-0279-5&quot;>10.1007/s00280-006-0279-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16832665/&quot;>https://pubmed.ncbi.nlm.nih.gov/16832665</a></p></li><li><p>Okamoto, I, et al., &amp; Saito, H (2006). Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. <i>Cancer chemotherapy and pharmacology</i> 57(3) 282–288. DOI:<a href=&quot;https://doi.org/10.1007/s00280-005-0051-2&quot;>10.1007/s00280-005-0051-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16028099/&quot;>https://pubmed.ncbi.nlm.nih.gov/16028099</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Amrubicin;
